Do analysts rate IMRN or TVRD?

Tvardi Therapeutics has a consensus price target of $53.60, indicating a potential upside of 1,488.15%. Given Tvardi Therapeutics' stronger consensus rating and higher possible upside, analysts plainly believe Tvardi Therapeutics is more favorable than Immuron. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Immuron 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Tvardi Therapeutics 1 Sell rating(s) 3 Hold rating(s) 2 Buy rating(s) 1 Strong Buy rating(s) 2.43

Which has preferable earnings and valuation, IMRN or TVRD?

Immuron has higher earnings, but lower revenue than Tvardi Therapeutics. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Immuron $4.72M 2.27 -$3.38M N/A N/A Tvardi Therapeutics $7.14M 4.43 -$18.21M -$3.10 N/A

Is IMRN or TVRD more profitable?

Immuron's return on equity of 0.00% beat Tvardi Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets Immuron N/A N/A N/A Tvardi Therapeutics N/A -64.17% -43.90%

Do analysts rate APLM or IMRN?

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Apollomics 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Immuron 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Which has preferable valuation & earnings, APLM or IMRN?

Immuron has lower revenue, but higher earnings than Apollomics. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Apollomics $8.50M 3.68 -$10.94M N/A N/A Immuron $4.72M 2.27 -$3.38M N/A N/A

Is APLM or IMRN more profitable?

Company Net Margins Return on Equity Return on Assets Apollomics N/A N/A N/A Immuron N/A N/A N/A

Do analysts recommend SNTI or IMRN?

Senti Biosciences currently has a consensus price target of $8.75, indicating a potential upside of 779.40%. Given Senti Biosciences' stronger consensus rating and higher probable upside, research analysts clearly believe Senti Biosciences is more favorable than Immuron. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Senti Biosciences 1 Sell rating(s) 0 Hold rating(s) 3 Buy rating(s) 1 Strong Buy rating(s) 2.80 Immuron 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Which has stronger earnings and valuation, SNTI or IMRN?

Immuron has higher revenue and earnings than Senti Biosciences. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Senti Biosciences $20K 1,549.71 -$61.44M -$1.92 N/A Immuron $4.72M 2.27 -$3.38M N/A N/A

Is SNTI or IMRN more profitable?

Immuron's return on equity of 0.00% beat Senti Biosciences' return on equity. Company Net Margins Return on Equity Return on Assets Senti Biosciences N/A -532.05% -103.35% Immuron N/A N/A N/A

Do analysts recommend IMRN or MYNZ?

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Immuron 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Mainz Biomed 1 Sell rating(s) 1 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.50

Which has higher earnings & valuation, IMRN or MYNZ?

Immuron has higher revenue and earnings than Mainz Biomed. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Immuron $4.72M 2.27 -$3.38M N/A N/A Mainz Biomed $659.94K 40.91 -$21.65M -$65.60 N/A

Is IMRN or MYNZ more profitable?

Company Net Margins Return on Equity Return on Assets Immuron N/A N/A N/A Mainz Biomed N/A N/A N/A

Do analysts prefer PLRZ or IMRN?

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Polyrizon 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Immuron 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Which has preferable earnings & valuation, PLRZ or IMRN?

Polyrizon has higher earnings, but lower revenue than Immuron. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Polyrizon N/A N/A -$3.34M N/A N/A Immuron $4.72M 2.27 -$3.38M N/A N/A

Is PLRZ or IMRN more profitable?

Company Net Margins Return on Equity Return on Assets Polyrizon N/A N/A N/A Immuron N/A N/A N/A

Does the media favor PLRZ or IMRN?

In the previous week, Polyrizon and Polyrizon both had 2 articles in the media. Immuron's average media sentiment score of 1.19 beat Polyrizon's score of 0.94 indicating that Immuron is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Polyrizon 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Immuron 0 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Immuron (IMRN) Competitors

$1.40 +0.19 (+15.95%)

As of 02:12 PM Eastern

Compare

IMRN vs. TVRD, APLM, SNTI, MYNZ, and PLRZ

Should you buy Immuron stock or one of its competitors? MarketBeat compares Immuron with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Immuron include Tvardi Therapeutics (TVRD), Apollomics (APLM), Senti Biosciences (SNTI), Mainz Biomed (MYNZ), and Polyrizon (PLRZ). These companies are all part of the "med - biomed/gene" industry.

How does Immuron compare to Tvardi Therapeutics?

Immuron (NASDAQ:IMRN) and Tvardi Therapeutics (NASDAQ:TVRD) are both small-cap medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their valuation, dividends, earnings, risk, profitability, analyst recommendations, institutional ownership and media sentiment.

Tvardi Therapeutics has a consensus price target of $53.60, indicating a potential upside of 1,488.15%. Given Tvardi Therapeutics' stronger consensus rating and higher possible upside, analysts plainly believe Tvardi Therapeutics is more favorable than Immuron.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Immuron	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Tvardi Therapeutics	1 Sell rating(s)	3 Hold rating(s)	2 Buy rating(s)	1 Strong Buy rating(s)	2.43

Immuron has higher earnings, but lower revenue than Tvardi Therapeutics.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Immuron	$4.72M	2.27	-$3.38M	N/A	N/A
Tvardi Therapeutics	$7.14M	4.43	-$18.21M	-$3.10	N/A

In the previous week, Immuron had 1 more articles in the media than Tvardi Therapeutics. MarketBeat recorded 2 mentions for Immuron and 1 mentions for Tvardi Therapeutics. Immuron's average media sentiment score of 1.19 beat Tvardi Therapeutics' score of 0.93 indicating that Immuron is being referred to more favorably in the media.

Company	Overall Sentiment
Immuron	Positive
Tvardi Therapeutics	Positive

0.1% of Immuron shares are owned by institutional investors. Comparatively, 44.7% of Tvardi Therapeutics shares are owned by institutional investors. 7.0% of Immuron shares are owned by company insiders. Comparatively, 3.1% of Tvardi Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

Immuron has a beta of 0.87, indicating that its share price is 13% less volatile than the broader market. Comparatively, Tvardi Therapeutics has a beta of 0.3, indicating that its share price is 70% less volatile than the broader market.

Immuron's return on equity of 0.00% beat Tvardi Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Immuron	N/A	N/A	N/A
Tvardi Therapeutics	N/A	-64.17%	-43.90%

Summary

Immuron and Tvardi Therapeutics tied by winning 7 of the 14 factors compared between the two stocks.

How does Immuron compare to Apollomics?

Apollomics (NASDAQ:APLM) and Immuron (NASDAQ:IMRN) are both small-cap medical companies, but which is the better business? We will compare the two companies based on the strength of their institutional ownership, analyst recommendations, profitability, media sentiment, risk, valuation, dividends and earnings.

Company	Net Margins	Return on Equity	Return on Assets
Apollomics	N/A	N/A	N/A
Immuron	N/A	N/A	N/A

Apollomics has a beta of 1.53, suggesting that its stock price is 53% more volatile than the broader market. Comparatively, Immuron has a beta of 0.87, suggesting that its stock price is 13% less volatile than the broader market.

19.1% of Apollomics shares are held by institutional investors. Comparatively, 0.1% of Immuron shares are held by institutional investors. 7.0% of Immuron shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

Immuron has lower revenue, but higher earnings than Apollomics.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Apollomics	$8.50M	3.68	-$10.94M	N/A	N/A
Immuron	$4.72M	2.27	-$3.38M	N/A	N/A

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Apollomics	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Immuron	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

In the previous week, Immuron had 1 more articles in the media than Apollomics. MarketBeat recorded 2 mentions for Immuron and 1 mentions for Apollomics. Apollomics' average media sentiment score of 1.87 beat Immuron's score of 1.19 indicating that Apollomics is being referred to more favorably in the media.

Company	Overall Sentiment
Apollomics	Very Positive
Immuron	Positive

Summary

Apollomics beats Immuron on 5 of the 8 factors compared between the two stocks.

How does Immuron compare to Senti Biosciences?

Senti Biosciences (NASDAQ:SNTI) and Immuron (NASDAQ:IMRN) are both small-cap medical companies, but which is the better business? We will compare the two businesses based on the strength of their earnings, analyst recommendations, media sentiment, dividends, risk, valuation, profitability and institutional ownership.

Immuron's return on equity of 0.00% beat Senti Biosciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Senti Biosciences	N/A	-532.05%	-103.35%
Immuron	N/A	N/A	N/A

In the previous week, Immuron had 1 more articles in the media than Senti Biosciences. MarketBeat recorded 2 mentions for Immuron and 1 mentions for Senti Biosciences. Senti Biosciences' average media sentiment score of 1.89 beat Immuron's score of 1.19 indicating that Senti Biosciences is being referred to more favorably in the media.

Company	Overall Sentiment
Senti Biosciences	Very Positive
Immuron	Positive

25.7% of Senti Biosciences shares are held by institutional investors. Comparatively, 0.1% of Immuron shares are held by institutional investors. 3.1% of Senti Biosciences shares are held by company insiders. Comparatively, 7.0% of Immuron shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

Senti Biosciences currently has a consensus price target of $8.75, indicating a potential upside of 779.40%. Given Senti Biosciences' stronger consensus rating and higher probable upside, research analysts clearly believe Senti Biosciences is more favorable than Immuron.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Senti Biosciences	1 Sell rating(s)	0 Hold rating(s)	3 Buy rating(s)	1 Strong Buy rating(s)	2.80
Immuron	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

Senti Biosciences has a beta of 2.09, suggesting that its stock price is 109% more volatile than the broader market. Comparatively, Immuron has a beta of 0.87, suggesting that its stock price is 13% less volatile than the broader market.

Immuron has higher revenue and earnings than Senti Biosciences.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Senti Biosciences	$20K	1,549.71	-$61.44M	-$1.92	N/A
Immuron	$4.72M	2.27	-$3.38M	N/A	N/A

Summary

Senti Biosciences beats Immuron on 8 of the 14 factors compared between the two stocks.

How does Immuron compare to Mainz Biomed?

Immuron (NASDAQ:IMRN) and Mainz Biomed (NASDAQ:MYNZ) are both small-cap medical companies, but which is the superior investment? We will compare the two companies based on the strength of their dividends, media sentiment, risk, profitability, institutional ownership, analyst recommendations, earnings and valuation.

Immuron has a beta of 0.87, indicating that its share price is 13% less volatile than the broader market. Comparatively, Mainz Biomed has a beta of 0.31, indicating that its share price is 69% less volatile than the broader market.

Immuron has higher revenue and earnings than Mainz Biomed.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Immuron	$4.72M	2.27	-$3.38M	N/A	N/A
Mainz Biomed	$659.94K	40.91	-$21.65M	-$65.60	N/A

0.1% of Immuron shares are owned by institutional investors. 7.0% of Immuron shares are owned by company insiders. Comparatively, 18.2% of Mainz Biomed shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Immuron	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Mainz Biomed	1 Sell rating(s)	1 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.50

Company	Net Margins	Return on Equity	Return on Assets
Immuron	N/A	N/A	N/A
Mainz Biomed	N/A	N/A	N/A

In the previous week, Immuron had 2 more articles in the media than Mainz Biomed. MarketBeat recorded 2 mentions for Immuron and 0 mentions for Mainz Biomed. Immuron's average media sentiment score of 1.19 beat Mainz Biomed's score of 0.00 indicating that Immuron is being referred to more favorably in the media.

Company	Overall Sentiment
Immuron	Positive
Mainz Biomed	Neutral

Summary

Immuron beats Mainz Biomed on 6 of the 9 factors compared between the two stocks.

How does Immuron compare to Polyrizon?

Polyrizon (NASDAQ:PLRZ) and Immuron (NASDAQ:IMRN) are both small-cap medical companies, but which is the better business? We will compare the two companies based on the strength of their profitability, institutional ownership, valuation, risk, analyst recommendations, media sentiment, earnings and dividends.

Polyrizon has higher earnings, but lower revenue than Immuron.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Polyrizon	N/A	N/A	-$3.34M	N/A	N/A
Immuron	$4.72M	2.27	-$3.38M	N/A	N/A

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Polyrizon	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Immuron	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

Polyrizon has a beta of -2.04, indicating that its stock price is 304% less volatile than the broader market. Comparatively, Immuron has a beta of 0.87, indicating that its stock price is 13% less volatile than the broader market.

0.1% of Immuron shares are held by institutional investors. 7.0% of Immuron shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Company	Net Margins	Return on Equity	Return on Assets
Polyrizon	N/A	N/A	N/A
Immuron	N/A	N/A	N/A

In the previous week, Polyrizon and Polyrizon both had 2 articles in the media. Immuron's average media sentiment score of 1.19 beat Polyrizon's score of 0.94 indicating that Immuron is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Polyrizon	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Immuron	0 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Summary

Immuron beats Polyrizon on 5 of the 6 factors compared between the two stocks.

Get Immuron News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding IMRN and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

IMRN vs. The Competition

Export

Metric	Immuron	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$10.70M	$3.40B	$6.42B	$12.60B
Dividend Yield	N/A	2.28%	2.75%	5.26%
P/E Ratio	N/A	18.93	21.28	26.32
Price / Sales	2.27	333.54	558.91	114.49
Price / Cash	N/A	125.26	43.49	56.90
Price / Book	1.68	7.29	10.60	7.34
Net Income	-$3.38M	$24.20M	$3.56B	$337.06M
7 Day Performance	31.00%	4.37%	3.21%	3.67%
1 Month Performance	62.13%	9.71%	6.51%	7.41%
1 Year Performance	-26.57%	63.73%	36.74%	37.93%

Immuron Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
IMRN Immuron	0.5656 of 5 stars	$1.40 +16.0%	N/A	-33.0%	$11.32M	$4.72M	N/A	N/A	Positive News
TVRD Tvardi Therapeutics	2.1154 of 5 stars	$3.41 -0.8%	$53.60 +1,471.4%	-88.7%	$32.55M	N/A	N/A	80
APLM Apollomics	1.003 of 5 stars	$14.44 +2.5%	N/A	+109.2%	$31.90M	$8.50M	N/A	45	Positive News Gap Up
SNTI Senti Biosciences	3.265 of 5 stars	$1.01 +1.8%	$8.75 +766.3%	-68.8%	$31.52M	$20K	N/A	4	Positive News
MYNZ Mainz Biomed	N/A	$3.47 +4.2%	N/A	+46.5%	$31.44M	$659.94K	N/A	30	Gap Up High Trading Volume

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:IMRN) was last updated on 5/29/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Immuron (IMRN) Competitors

IMRN vs. TVRD, APLM, SNTI, MYNZ, and PLRZ

How does Immuron compare to Tvardi Therapeutics?

Summary

How does Immuron compare to Apollomics?

Summary

How does Immuron compare to Senti Biosciences?

Summary

How does Immuron compare to Mainz Biomed?

Summary

How does Immuron compare to Polyrizon?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

IMRN vs. The Competition

Immuron Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Immuron (IMRN) Competitors

IMRN vs. TVRD, APLM, SNTI, MYNZ, and PLRZ

How does Immuron compare to Tvardi Therapeutics?

Do analysts rate IMRN or TVRD?

Which has preferable earnings and valuation, IMRN or TVRD?

Does the media refer more to IMRN or TVRD?

Do institutionals and insiders believe in IMRN or TVRD?

Which has more risk and volatility, IMRN or TVRD?

Is IMRN or TVRD more profitable?

Summary

How does Immuron compare to Apollomics?

Is APLM or IMRN more profitable?

Which has more volatility & risk, APLM or IMRN?

Do insiders & institutionals hold more shares of APLM or IMRN?

Which has preferable valuation & earnings, APLM or IMRN?

Do analysts rate APLM or IMRN?

Does the media refer more to APLM or IMRN?

Summary

How does Immuron compare to Senti Biosciences?

Is SNTI or IMRN more profitable?

Does the media refer more to SNTI or IMRN?

Do institutionals and insiders have more ownership in SNTI or IMRN?

Do analysts recommend SNTI or IMRN?

Which has more volatility and risk, SNTI or IMRN?

Which has stronger earnings and valuation, SNTI or IMRN?

Summary

How does Immuron compare to Mainz Biomed?

Which has more risk and volatility, IMRN or MYNZ?

Which has higher earnings & valuation, IMRN or MYNZ?

Do insiders & institutionals hold more shares of IMRN or MYNZ?

Do analysts recommend IMRN or MYNZ?

Is IMRN or MYNZ more profitable?

Does the media prefer IMRN or MYNZ?

Summary

How does Immuron compare to Polyrizon?

Which has preferable earnings & valuation, PLRZ or IMRN?

Do analysts prefer PLRZ or IMRN?

Which has more risk & volatility, PLRZ or IMRN?

Do insiders & institutionals believe in PLRZ or IMRN?

Is PLRZ or IMRN more profitable?

Does the media favor PLRZ or IMRN?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

IMRN vs. The Competition

Immuron Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools